Maxwell Thomas Laws

Maxwell Thomas Laws

Auto-generated profile, based on publicly available information

Maxwell Thomas Laws

Neurosurgery Unit for Pituitary and Inheritable Diseases, National Institute of Neurological Diseases and Stroke, Bethesda, Maryland, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2020 in BMC Medicine
Verified
Journal Article
Open access
PDF file
HMHuijing Ma
Huijing Ma
JHJiani Hu
Jiani Hu
JTJie Tian
Jie Tian
XZXi Zhou
Xi Zhou
HLHui Li
Hui Li
JSJianbo Shao
Jianbo Shao
Background: Compared to adults, there are relatively few studies on COVID-19 infection in children, and even less focusing on the unique features of COVID-19 in children in terms of laboratory findings, locations of computerized tomography (CT) lesions, and the role of CT in evaluating clinical recovery. The objective of this study is to report the results from patients at Wuhan Children’s Hospital, located within the initial center of the outbreak.Methods: Clinical, imaging, and laboratory data of 76 children were collected retrospectively and analyzed with the Fisher exact test and Cox regression statistical methods.Results: Among 50 children with a positive COVID-19 real-time reverse-transcriptase polymerase chain reaction (PCR), five had negative PCR results initially but showed positive results in subsequent tests. Eight (16%) patients had lymphopenia, seven (14%) with thrombocytopenia, four (8%) with lymphocytosis, two (4%) with thrombocytosis, ten (20%) with elevated C-reactive protein, four (8%) with hemoglobin above, and six (12%) with below standard reference values. Seven (14%) of the 50 had no radiologic evidence of disease on chest CT. For the 43 patients who had abnormal CT findings, in addition to previously reported patterns of ground-glass opacity (67%), local patchy shadowing (37%), local bilateral patchy shadowing (21%), and lesion location of lower lobes (65%), other CT features include that an overwhelming number of pediatric patients had lesions in the subpleural area (95%) and 22 of the 28 lower lobe lesions were in the posterior segment (78%). Lesions in most of the 15 patients (67%) who received chest CT at discharge were not completely absorbed, and 26% of these pediatric patients had CT lesions that were either unchanged or worse.Conclusions: There were a few differences between COVID-19 children and COVID-19 adults in terms of laboratory findings and CT characteristics. CT is a powerful tool to detect and characterize COVID-19 pneumonia but has little utility in evaluating clinical recovery for children. These results oppose current COVID-19 hospital discharge criteria in China, as one requirement is that pulmonary imaging must show significant lesion absorption prior to discharge. These differences between pediatric and adult cases of COVID-19 may necessitate pediatric-specific discharge criteria.

5 March 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MLMaxwell T. Laws
Maxwell T. Laws
RBRobin E. Bonomi
Robin E. Bonomi
SKSwatabdi Kamal
Swatabdi Kamal
DGDavid J. Gelovani
David J. Gelovani
JLJeremy Llaniguez
Jeremy Llaniguez
JGJuri G. George Gelovani
Juri G. George Gelovani
HDAC class IIa enzymes (HDAC4, 5, 7, 9) are important for glioma progression, invasion, responses to TMZ and radiotherapy, and prognosis. In this study, we demonstrated the efficacy of PET/CT/(MRI) with [18F]TFAHA for non-invasive and quantitative imaging of HDAC class IIa expression-activity in intracerebral 9L and U87-MG gliomas in rats. Increased accumulation of [18F]TFAHA in 9L and U87-MG tumors was observed at 20 min post radiotracer administration with SUV of 1.45 ± 0.05 and 1.08 ± 0.05, respectively, and tumor-to-cortex SUV ratios of 1.74 ± 0.07 and 1.44 ± 0.03, respectively. [18F]TFAHA accumulation was also observed in normal brain structures known to overexpress HDACs class IIa: hippocampus, n.accumbens, PAG, and cerebellum. These results were confirmed by immunohistochemical staining of brain tissue sections revealing the upregulation of HDACs 4, 5, and 9, and HIF-1α, hypoacetylation of H2AK5ac, H2BK5ac, H3K9ac, H4K8ac, and downregulation of KLF4. Significant reduction in [18F]TFAHA accumulation in 9L tumors was observed after administration of HDACs class IIa specific inhibitor MC1568, but not the SIRT1 specific inhibitor EX-527. Thus, PET/CT/(MRI) with [18F]TFAHA can facilitate studies to elucidate the roles of HDAC class IIa enzymes in gliomagenesis and progression and to optimize therapeutic doses of novel HDACs class IIa inhibitors in gliomas.

1 March 2019 in European Journal of Radiology
Verified
Journal Article
Closed access
YCYan-Li Chen
Yan-Li Chen
RLRui Li
Rui Li
TCTian-wu Chen
Tian-wu Chen
JOJing Ou
Jing Ou
XZXiao-Ming Zhang
Xiao-Ming Zhang
JHJiani Hu
Jiani Hu

27 July 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RBRobin Bonomi
Robin Bonomi
VPVadim Popov
Vadim Popov
MLMaxwell T. Laws
Maxwell T. Laws
DGDavid Gelovani
David Gelovani
AMAnjoy Majhi
Anjoy Majhi
JGJuri G. George Gelovani
Juri G. George Gelovani

1 January 2020 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
MLMaxwell T Laws
Maxwell T Laws
RBRobin Bonomi
Robin Bonomi
DGDavid J Gelovani
David J Gelovani
JLJeremy Llaniguez
Jeremy Llaniguez
XLXin Lu
Xin Lu
JGJuri G. George Gelovani
Juri G. George Gelovani
Several studies demonstrated that glioblastoma multiforme progression and recurrence is linked to epigenetic regulatory mechanisms. Sirtuin 1 (SIRT1) plays an important role in glioma progression, invasion, and treatment response and is a potential therapeutic target. The aim of this study is to test the feasibility of 2-[18F]BzAHA for quantitative imaging of SIRT1 expression–activity and monitoring pharmacologic inhibition in a rat model of intracerebral glioma. Sprague Dawley rats bearing 9L (N = 12) intracerebral gliomas were injected with 2-[18F]BzAHA (300–500 µCi/animal i.v.) and dynamic positron-emission tomography (PET) imaging was performed for 60 min. Then, SIRT1 expression in 9L tumors (N = 6) was studied by immunofluorescence microscopy (IF). Two days later, rats with 9L gliomas were treated either with SIRT1 specific inhibitor EX-527 (5 mg/kg, i.p.; N = 3) or with histone deacetylases class IIa specific inhibitor MC1568 (30 mg/kg, i.p.; N = 3) and 30 min later were injected i.v. with 2-[18F]BzAHA. PET-computerized tomography-magnetic resonance (PET/CT/MR) images acquired after EX-527 and MC1568 treatments were co-registered with baseline images. Standard uptake values (SUVs) of 2-[18F]BzAHA in 9L tumors measured at 20 min post-radiotracer administration were 1.11 ± 0.058 and had a tumor-to-brainstem SUV ratio of 2.73 ± 0.141. IF of 9L gliomas revealed heterogeneous upregulation of SIRT1, especially in hypoxic and peri-necrotic regions. Significant reduction in 2-[18F]BzAHA SUV and distribution volume in 9L tumors was observed after administration of EX-527, but not MC1568. PET/CT/MRI with 2-[18F]BzAHA can facilitate studies to elucidate the roles of SIRT1 in gliomagenesis and progression, as well as to optimize therapeutic doses of novel SIRT1 inhibitors.

8 February 2018 in Molecular Imaging and Biology
Verified
Journal Article
Open access
PDF file
RBRobin E. Bonomi
Robin E. Bonomi
MLMaxwell Laws
Maxwell Laws
VPVadim Popov
Vadim Popov
SKSwatabdi Kamal
Swatabdi Kamal
SPShreya Potukutchi
Shreya Potukutchi
JGJuri G. George Gelovani
Juri G. George Gelovani
The purpose of this study was to develop a SIRT2-specific substrate-type radiotracer for non-invasive PET imaging of epigenetic regulatory processes mediated by SIRT2 in normal and disease tissues.